[
  {
    "ts": null,
    "headline": "HHS to Wind Down mRNA Vaccine Programs",
    "summary": "The Department of Health and Human Services said it is winding down its mRNA vaccine-development activities under the Biomedical Advanced Research and Development Authority.",
    "url": "https://finnhub.io/api/news?id=a714837d65fea79f318c0c01ada6295ba08f068bbf32d514ad328f33ebc70cd3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754434320,
      "headline": "HHS to Wind Down mRNA Vaccine Programs",
      "id": 136232752,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The Department of Health and Human Services said it is winding down its mRNA vaccine-development activities under the Biomedical Advanced Research and Development Authority.",
      "url": "https://finnhub.io/api/news?id=a714837d65fea79f318c0c01ada6295ba08f068bbf32d514ad328f33ebc70cd3"
    }
  },
  {
    "ts": null,
    "headline": "Moderna: RSV Upside Slim, Cash Burn Heavy",
    "summary": "Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read an analysis of MRNA stock now.",
    "url": "https://finnhub.io/api/news?id=dec74b30d659c6359af7f503f4d507940028530e679a7fb806c41897811119b5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754391981,
      "headline": "Moderna: RSV Upside Slim, Cash Burn Heavy",
      "id": 136213977,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2170076105/image_2170076105.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read an analysis of MRNA stock now.",
      "url": "https://finnhub.io/api/news?id=dec74b30d659c6359af7f503f4d507940028530e679a7fb806c41897811119b5"
    }
  },
  {
    "ts": null,
    "headline": "Lipid Nanoparticles Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034",
    "summary": "Growth in the Lipid Nanoparticles (LNPs) market is driven by increasing demand for mRNA-based therapeutics and advances in delivery systems. LNPs, vital in protecting and delivering mRNA molecules, expand beyond infectious diseases into cancer immunotherapy and genetic therapies. The U.S. leads in this market with strong biotech roots. Key players, including Moderna and BioNTech, invest in R&D and partnerships to enhance LNP applications. The therapeutics segment holds significant market share,",
    "url": "https://finnhub.io/api/news?id=99856ad330416ed59c17e6f36fe8966532e1d75ec8625b139d80259f5540664c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754388000,
      "headline": "Lipid Nanoparticles Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034",
      "id": 136212875,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Growth in the Lipid Nanoparticles (LNPs) market is driven by increasing demand for mRNA-based therapeutics and advances in delivery systems. LNPs, vital in protecting and delivering mRNA molecules, expand beyond infectious diseases into cancer immunotherapy and genetic therapies. The U.S. leads in this market with strong biotech roots. Key players, including Moderna and BioNTech, invest in R&D and partnerships to enhance LNP applications. The therapeutics segment holds significant market share,",
      "url": "https://finnhub.io/api/news?id=99856ad330416ed59c17e6f36fe8966532e1d75ec8625b139d80259f5540664c"
    }
  },
  {
    "ts": null,
    "headline": "Cancer Vaccine Research Report 2025-2035 | Market Accelerates with Key Players Like Merck and Moderna, Backed by Pharma-Biotech Collaborations and Academic Partnerships",
    "summary": "The global cancer vaccine market is experiencing robust growth driven by rising cancer cases, advancements in immunotherapy, and novel vaccine development technologies. Both preventive (e.g., HPV, HBV) and therapeutic vaccines are gaining traction, supported by increased R&D investments, especially in mRNA platforms and neoantigen vaccines. Innovations like AI and genome sequencing are enhancing personalized therapies, while FDA approvals boost confidence in clinical efficacy. With strong health",
    "url": "https://finnhub.io/api/news?id=a2f69b323d53e66fb01bddee62c9fbb8526467370f91cdf85555ed9ea70d5d9d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754380980,
      "headline": "Cancer Vaccine Research Report 2025-2035 | Market Accelerates with Key Players Like Merck and Moderna, Backed by Pharma-Biotech Collaborations and Academic Partnerships",
      "id": 136212353,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The global cancer vaccine market is experiencing robust growth driven by rising cancer cases, advancements in immunotherapy, and novel vaccine development technologies. Both preventive (e.g., HPV, HBV) and therapeutic vaccines are gaining traction, supported by increased R&D investments, especially in mRNA platforms and neoantigen vaccines. Innovations like AI and genome sequencing are enhancing personalized therapies, while FDA approvals boost confidence in clinical efficacy. With strong health",
      "url": "https://finnhub.io/api/news?id=a2f69b323d53e66fb01bddee62c9fbb8526467370f91cdf85555ed9ea70d5d9d"
    }
  }
]